The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer

December 12, 2019

Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.

Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.

The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.